Kestra Medical Technologies (KMTS) Net Income towards Common Stockholders (2024 - 2026)

Kestra Medical Technologies (KMTS) has reported Net Income towards Common Stockholders for 3 consecutive years, with -$38.8 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Net Income towards Common Stockholders rose 29.83% year-over-year to -$38.8 million; the TTM figure through Apr 2026 stood at -$131.6 million (down 4.34% YoY), while the FY2026 annual figure was -$131.6 million, down 4.34% from the prior year.
• Net Income towards Common Stockholders eased to -$38.8 million in Q2 2026 per KMTS's latest filing, from -$34.2 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at -$22.3 million in Q3 2024 and bottomed at -$55.3 million in Q2 2025.
• Historically, Net Income towards Common Stockholders has averaged -$30.5 million across 3 years, with a median of -$25.3 million in 2025.
• Annual changes were most pronounced in 2025 — Net Income towards Common Stockholders sank 127.96% — and 2026, when it advanced 29.83%.
• Kestra Medical Technologies' Net Income towards Common Stockholders stood at -$23.7 million in 2024, then slumped by 38.39% to -$32.8 million in 2025, then decreased by 18.45% to -$38.8 million in 2026.
• Business Quant data shows KMTS's Net Income towards Common Stockholders at -$38.8 million in Q2 2026, -$34.2 million in Q1 2026, and -$32.8 million in Q4 2025.